Humulin - instructions for use, analogs, reviews and release forms (suspension for subcutaneous injection, solution in ampoules or cartridges for injection NPH, M3, Regular) drugs for the treatment of diabetes in adults, children and pregnancy

In this article, you can read the instructions for using the drug Humulin. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Khumulin in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues Khumulina in the presence of existing structural analogs.Use for the treatment of diabetes and diabetes insipidus in adults, children, as well as during pregnancy and lactation.

Humulin - DNA-recombinant human insulin.

Khumulin NPH

Is a preparation of insulin of average duration of action.

The main effect of the drug is the regulation of glucose metabolism. In addition, it has an anabolic effect. In muscle and other tissues (with the exception of the brain), insulin causes rapid intracellular transport of glucose and amino acids, accelerates protein anabolism. Insulin promotes the conversion of glucose into glycogen in the liver, inhibits gluconeogenesis and stimulates the conversion of excess glucose into fat.

Khumulin Regular

It is a short-acting insulin preparation.

Humulin M3

DNA-recombinant human insulin of medium duration. It is a two-phase suspension (30% of Humulin Regular and 70% of Khumulina NPH).

The main effect of the drug is the regulation of glucose metabolism. In addition, it has an anabolic effect. In muscle and other tissues (with the exception of the brain), insulin causes rapid intracellular transport of glucose and amino acids, accelerates protein anabolism.Insulin promotes the conversion of glucose into glycogen in the liver, inhibits gluconeogenesis and stimulates the conversion of excess glucose into fat.

Composition

Human insulin + excipients.

Insulin biphasic (human genetically engineered) + auxiliary substances (Humulin M3).

Pharmacokinetics

Humulin NPH is a medication of insulin of average duration of action. The beginning of the drug - 1 hour after the injection, the maximum effect of the action - between 2 and 8 hours, the duration of the action - 18-20 hours. Individual differences in the activity of insulin depend on such factors as dose, choice of injection site, physical activity of the patient.

Indications

• Diabetes mellitus in the presence of indications for carrying out insulin therapy;
• the newly diagnosed diabetes mellitus;
• pregnancy with type 2 diabetes mellitus (non-insulin-dependent).

Forms of release

Suspension for subcutaneous administration (Humulin NPH and M3).

Solution for injections in bottles and cartridges QuickPhen (Khumulin Regular) (injections in ampoules for injections).

Instructions for use and dosage

NPH suspension

The dose is set by the doctor individually depending on the level of glycemia.

The drug should be administered subcutaneously, possibly by intramuscular injection. Intravenous introduction Humulin NPH is contraindicated!

Subcutaneously, the drug is injected into the shoulder, thigh, buttock, or abdomen. The injection site must be alternated so that the same place is used no more often than once a month.

With n / to the introduction, care must be taken to avoid getting into the blood vessel. After injection, do not massage the injection site. Patients should be trained in the proper use of insulin delivery devices.

Rules for preparation and administration of the drug

Cartridges and bottles Humulin NPH before use should be rolled between the palms 10 times and shake, turning 180 degrees also 10 times to resuspend insulin until it becomes a homogeneous cloudy liquid or milk. Do not shake vigorously. this can lead to the appearance of foam, which can interfere with the correct dose set.

Cartridges and bottles should be carefully checked. Do not use insulin if there are flakes after mixing, if solid white particles adhere to the bottom or walls of the vial, creating the effect of a frosty pattern.

The device of cartridges does not allow to mix their contents with other insulins directly in the cartridge. Cartridges are not intended for refilling.

The contents of the vial should be dialed into an insulin syringe that corresponds to the concentration of insulin administered, and enter the desired dose of insulin according to the doctor's instructions.

When using cartridges, follow the manufacturer's instructions for refilling the cartridge and attaching the needle. The drug should be administered in accordance with the manufacturer's instructions for the syringe pen.

Using the outer needle cap, immediately after insertion, unscrew the needle and safely destroy it. Removing the needle immediately after injection provides sterility, prevents leakage, air ingress and possible clogging of the needle. Then put the cap on the handle.

Needles should not be reused. Needles and syringe-pens should not be used by others. Cartridges and bottles are used until they become empty, after which they should be discarded.

Humulin NPH can be administered in combination with Humulin Regular. For this, short-acting insulin should be injected into the syringe first to prevent longer-lasting exposure to the insulin bottle.It is desirable to introduce the mixture directly after mixing. To introduce the exact amount of insulin of each type, you can use a separate syringe for Khumulina Regular and Khumulina NPH.

Always use an insulin syringe that matches the concentration of insulin administered.

Mortar Regular

The dose is determined by the doctor individually depending on the level of glycemia.

The drug should be administered subcutaneously, intravenously, possibly by intramuscular injection.

The drug is injected into the shoulder, thigh, buttock or abdomen. The injection site must be alternated so that the same place is used no more often than once a month.

With n / to the introduction, care must be taken to avoid getting into the blood vessel. After injection, do not massage the injection site. Patients should be trained in the proper use of insulin delivery devices.

Rules for preparation and administration of the drug

Cartridges and vials of Khumulina Regular do not require resuspension and can be used only if their contents are a clear, colorless liquid with no visible particles.

Cartridges and bottles should be carefully checked. Do not use the drug if it has flakes, if solid white particles adhere to the bottom or walls of the vial, creating the effect of a frosty pattern.

The device of cartridges does not allow to mix their contents with other insulins directly in the cartridge. Cartridges are not intended for refilling.

The contents of the vial should be dialed into an insulin syringe that corresponds to the concentration of insulin administered, and enter the desired dose of insulin according to the doctor's instructions.

When using cartridges, follow the manufacturer's instructions for refilling the cartridge and attaching the needle. The drug should be administered in accordance with the manufacturer's instructions for the syringe pen.

Using the outer needle cap, immediately after insertion, unscrew the needle and safely destroy it. Removing the needle immediately after injection provides sterility, prevents leakage, air ingress and possible clogging of the needle. Then put the cap on the handle.

Needles should not be reused. Needles and syringe-pens should not be used by others.Cartridges and bottles are used until they become empty, after which they should be discarded.

Humulin Regular can be administered in combination with Humulin NPH. For this, short-acting insulin should be injected into the syringe first to prevent longer-lasting exposure to the insulin bottle. It is desirable to introduce the mixture directly after mixing. To introduce the exact amount of insulin of each species, you can use a separate syringe for Khumulina Regular and Khumulina NPH.

Always use an insulin syringe that matches the concentration of insulin administered.

Suspension M3

The drug should be administered subcutaneously, possibly by intramuscular injection. Intravenous introduction Humulin M3 is contraindicated!

Side effect

• hypoglycemia;
• loss of consciousness;
• hyperemia, edema or itching at the injection site (usually terminate for a period of several days to several weeks);
• systemic allergic reactions (occur less often, but are more serious) - generalized itching, difficulty breathing, dyspnea, lowering blood pressure, increased heart rate, increased sweating;
• the likelihood of developing lipodystrophy is minimal.

Contraindications

• hypoglycemia;
• hypersensitivity to insulin or to one of the components of the drug.

Application in pregnancy and lactation

In pregnancy, it is especially important to maintain good control of glycemia in patients with diabetes mellitus. In pregnancy, the need for insulin usually decreases in 1 trimester and rises in 2 and 3 trimesters.

Patients with diabetes are advised to inform the doctor about the onset or planning of pregnancy.

Patients with diabetes during lactation (breastfeeding) may need to adjust the dose of insulin, diet, or both.

In studies of genetic toxicity, human insulin did not have a mutagenic effect.

special instructions

Transfer of a patient to another type of insulin or to a preparation of insulin with a different trade name should occur under strict medical supervision. Changes in the activity of insulin, its type (eg, M3, NPH, Regular), species (pork, human insulin, human insulin analog) or production method (DNA-recombinant insulin or insulin of animal origin) may lead to the need for dose adjustment.

The need for dose adjustment may be required already at the first injection of the human insulin drug after an insulin preparation of animal origin or gradually within a few weeks or months after the transfer.

The need for insulin may decrease with insufficient adrenal function, pituitary gland or thyroid gland, with renal or hepatic insufficiency.

With some diseases or emotional stress, the need for insulin can increase.

Dose adjustment may also be required if the exercise is increased or when a normal diet changes.

Symptoms-precursors of hypoglycemia against the background of the introduction of human insulin in some patients may be less pronounced or different from those that were observed in them against the background of the introduction of insulin of animal origin. When normalizing blood glucose levels, for example, as a result of intensive insulin therapy, all or some of the symptoms that precede hypoglycemia may disappear, which patients should be informed about.

Symptoms-precursors of hypoglycemia may change or be less pronounced with prolonged course of diabetes mellitus, diabetic neuropathy or with the simultaneous use of beta-blockers.

In some cases, local allergic reactions may be caused by causes not associated with the action of the drug, for example, skin irritation with a cleansing agent or improper injection.

In rare cases of development of systemic allergic reactions, immediate treatment is required. Sometimes it may be necessary to change insulin or conduct desensitization.

Impact on the ability to drive vehicles and manage mechanisms

During hypoglycemia, the patient's ability to concentrate and reduce the speed of psychomotor reactions may worsen. This can be dangerous in situations in which these abilities are particularly necessary (driving or controlling machinery). It should be recommended that patients take precautions to avoid hypoglycemia while driving a car. This is especially important for patients with mild or absent symptoms-precursors of hypoglycemia or with frequent development of hypoglycemia. In such cases, the doctor should assess the advisability of driving a car patient.

Drug Interactions

Hugulina's hypoglycemic effect is reduced by oral contraceptives, corticosteroids, thyroid hormone preparations, thiazide diuretics, diazoxide, tricyclic antidepressants.

Hugulina's hypoglycemic action is enhanced by oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), sulfonamides, MAO inhibitors, beta adrenoblockers, ethanol (alcohol) and ethanol-containing drugs.

Beta-adrenoblockers, clonidine, reserpine can mask the manifestation of symptoms of hypoglycemia.

Pharmaceutical interaction

Effects arising from the mixing of human insulin with animal insulin or human insulin produced by other manufacturers have not been studied.

Analogues of the drug Humulin

Structural analogs for the active substance (insulins):

• Actrapid;
• Apidra;
• Apidra SoloStar;
• B-Insulin S.Ts. Berlin-Chemie;
• Berselsulin;
• Biosulin;
• Brinsulmidi;
• Brinsulrapi;
• Gensulin;
• Depo insulin C;
• Isofan Insulin;
• Iletin;
• Insulin aspart;
• Insulin glargine;
• Insulin glulisine;
• Insulin Detemir;
• Insulin Lente;
• Insulin Maxiprapid;
• Insulin is a soluble neutral;
• Pork insulin highly purified;
• Insulin Semilente;
• Insulin Ultralente;
• Human genetically insulin insulin;
• Human insulin is semisynthetic;
• Human insulin is recombinant;
• Insulin Long QMS;
• Insulin Ultralong SMK;
• Insulong;
• Insuman;
• Insuran;
• Inutral;
• Comb Insulin C;
• Lantus;
• Levemir;
• Mixtard;
• Monoinsulin;
• Monotard;
• NovoMiks;
• Novorapid Penfill;
• NovoRapid FlexPen;
• Pensulin;
• Protamine Insulin;
• Protafan;
• Raizodeg;
• Rinsulin;
• Rosinsulin;
• Tresib Penfill;
• Tresiba FlexTach;
• Ultradard;
• Homolong;
• Homorap;
• Humalog;
• Humodar;
• Khumulin L;
• Humulin Regular;
• Humulin M3;
• Khumulin NPH.

Similar medicines:

Other medicines: